

Olivier Aubert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/614644/publications.pdf>

Version: 2024-02-01

41
papers

2,732
citations

257450

24
h-index

361022

35
g-index

43
all docs

43
docs citations

43
times ranked

3416
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 293-304.	6.1	244
2	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1721-1731.	6.1	243
3	Organ procurement and transplantation during the COVID-19 pandemic. <i>Lancet, The</i> , 2020, 395, e95-e96.	13.7	222
4	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1912-1923.	6.1	208
5	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4923.	2.3	191
6	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	6.0	146
7	Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection. <i>Circulation</i> , 2017, 135, 917-935.	1.6	139
8	COVID-19 pandemic and worldwide organ transplantation: a population-based study. <i>Lancet Public Health, The</i> , 2021, 6, e709-e719.	10.0	139
9	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	5.1	125
10	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	5.2	117
11	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 702-715.	6.1	111
12	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	6.1	94
13	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	4.7	76
14	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	8.4	76
15	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. <i>American Journal of Transplantation</i> , 2021, 21, 1285-1294.	4.7	69
16	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	4.7	60
17	Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation. <i>Circulation</i> , 2020, 141, 1954-1967.	1.6	50
18	Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 625-639.	6.1	48

#	ARTICLE	IF	CITATIONS
19	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	4.5	41
20	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	5.2	40
21	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	6.1	40
22	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	5.2	38
23	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1761-1770.	6.1	36
24	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 2448-2458.	4.7	31
25	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1084-1096.	6.1	28
26	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	12.3	25
27	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	1.9	24
28	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1365-1374.	4.7	20
29	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	1.0	15
30	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , 2020, 33, 849-857.	1.6	12
31	The Case Post-transplant allograft dysfunction. <i>Kidney International</i> , 2013, 83, 765-767.	5.2	8
32	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. <i>Transplant International</i> , 2016, 29, 1205-1215.	1.6	7
33	Autoimmune Neutropenia After Kidney Transplantation. <i>Transplantation</i> , 2014, 97, 725-729.	1.0	5
34	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1597-1604.	0.7	2
35	Towards a precision medicine approach to positive crossmatch transplantation: Impact on response to therapy. <i>American Journal of Transplantation</i> , 2019, 19, 1611-1613.	4.7	1
36	A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. <i>Transplant International</i> , 2021, 34, 1506-1516.	1.6	1

#	ARTICLE	IF	CITATIONS
37	The Number of Discarded Kidneys Is Likely Much Larger Than Reported”Reply. JAMA Internal Medicine, 2020, 180, 467.	5.1	0
38	Authors”™ Reply. Journal of the American Society of Nephrology: JASN, 2021, 32, 1264-1265.	6.1	0
39	FC 114: Monoclonal Gammopathy in Kidney Transplanted Patients: Novel Insights into Long-Term Outcomes. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
40	MO1021: Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
41	FC 105: Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0